Award of SPE2D220D0086 BICALUTAMIDE NATIONAL CONTRACT
ID: SPE2D220D0086Type: Special Notice
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

Original Source

https://sam.gov/opp/92764097db6b4e06b4b9db70acb3f692/view
Timeline
    Description

    Special Notice DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is procuring Bicalutamide National Contract. Bicalutamide is typically used as a medication for the treatment of prostate cancer.

    Point(s) of Contact
    Denise Taubman
    (215) 737-6877
    denise.taubman@dla.mil
    Files
    Title
    Posted
    Bicalutamide FO Award signed 1.8.2020.pdf
    SPE2D2-20-D-0086 P00004.pdf
    SPE2D220D0086-P00003.pdf
    SPE2D220D0086P00002.pdf
    Lifecycle
    Title
    Type
    Award of SPE2D220D0086 BICALUTAMIDE NATIONAL CONTRACT
    Currently viewing
    Special Notice
    Similar Opportunities
    Finasteride Tablets
    Active
    Dept Of Defense
    Special Notice: DEPT OF DEFENSE - DEFENSE LOGISTICS AGENCY is seeking Finasteride Tablets. Finasteride Tablets are typically used for the treatment of male pattern hair loss and benign prostatic hyperplasia. This procurement is for the incorporation of new clauses into an existing contract.
    SPE2D220R0063 BUPROPION XL AMENDMENT 0002
    Active
    Dept Of Defense
    Special Notice DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is seeking BUPROPION XL. This procurement is for drugs and biologicals under PSC code 6505. The primary contact for this procurement is Catherine Gilbert (catherine.gilbert@dla.mil, 2157374778) and the secondary contact is Denise Taubman (denise.taubman@dla.mil, 2157376877). The notice includes Amendment 0002, which incorporates telecommunication clauses. The solicitation is not reopened and the closing date is not extended. BUPROPION XL is typically used for medical purposes.
    IBUPROFEN 400MG, 600MG, 800MG TABLETS NATIONAL CONTRACT
    Active
    Dept Of Defense
    Special Notice DEPT OF DEFENSE is seeking IBUPROFEN 400MG, 600MG, 800MG TABLETS. This medication is typically used for pain relief, reducing inflammation, and lowering fever. The notice is from the DEFENSE LOGISTICS AGENCY, DLA TROOP SUPPORT. The primary contact for this procurement is Denise Taubman (denise.taubman@dla.mil, 2157376877) and the secondary contact is Catherine Gilbert (catherine.gilbert@dla.mil, 2157374778). The notice includes AMENDMENT 00009 to incorporate telecommunication clauses into the solicitation.
    Norgestimate/Ethinyl Estradiol Tablets
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is soliciting offers for the supply of Norgestimate/Ethinyl Estradiol Tablets, a pharmaceutical product essential for oral contraceptive use. The procurement aims to establish a contract that outlines specific supply requirements, estimated quantities for multiple option years, and compliance with federal regulations, including ethical conduct and labor standards. This solicitation is critical for ensuring the availability of these contraceptive medications to support military personnel and their families. Interested contractors must submit their offers via the Defense Logistics Agency Internet Bid Board System (DIBBS) by January 21, 2025, and are encouraged to contact Kyle Lewicki at kyle.lewicki@dla.mil or Jason C. Wray at Jason.Wray@dla.mil for further information.
    Norgestimate/Ethinyl Estradiol Oral Tablets
    Active
    Dept Of Defense
    Special Notice DEPT OF DEFENSE is seeking Norgestimate/Ethinyl Estradiol Oral Tablets. These tablets are typically used for oral contraception.
    6505--Abiraterone Tablets
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is soliciting proposals for the supply of Abiraterone Acetate Tablets through its Pharmaceutical Prime Vendor Program. Offerors are required to comply with the Drug Supply Chain Security Act (DSCSA) and Good Manufacturing Practices (cGMP), providing a unique 11-digit National Drug Code (NDC) for each drug, along with pricing for the base year and four optional years, including a Cost Recovery Fee. This procurement is crucial for ensuring consistent availability and competitive pricing of essential medications for federal healthcare users, particularly veterans. Interested parties must submit their proposals by the extended deadline of January 8, 2025, at 2:30 PM CST, and can contact Contract Specialist Richard Mahario at Richard.Mahario@va.gov for further information.
    Norgestimate/Ethinyl Estradiol Oral Tablets
    Active
    Dept Of Defense
    Special Notice DEPT OF DEFENSE is modifying contract SPE2D220D0090 to correct an administrative error for the procurement of Norgestimate/Ethinyl Estradiol Oral Tablets. Norgestimate/Ethinyl Estradiol Oral Tablets are typically used for contraception and hormone replacement therapy.
    Metformin HCL
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is planning to issue a national requirements contract for Metformin HCL ER. The contract will establish a national supply source to provide Metformin HCL ER Tablets in various quantities and bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The solicitation will be posted on DLA Bid Board System (DIBBS) and Sam.gov. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is August 2021.
    Valsartan
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Valsartan, a drug used to treat high blood pressure and heart failure. The contract will include Valsartan tablets in various strengths and quantities. It will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The solicitation will be posted on the DLA Bid Board System and beta.SAM.gov, with a projected solicitation date in June 2021. Interested parties should contact Christopher Newman for more information.
    Lamotrigine
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for the procurement of various dosages of Lamotrigine ER, a pharmaceutical product. This solicitation (SPE2D2-25-R-0002) outlines the submission procedures for interested contractors, emphasizing the requirement for electronic submissions via the Defense Logistics Agency Internet Bid Board System (DIBBS) by the deadline of January 9, 2025. Lamotrigine is a critical medication used in the treatment of epilepsy and bipolar disorder, making this procurement essential for maintaining adequate supplies for military and healthcare facilities. For further inquiries, interested parties can contact Nancy Fernandez at nancy.fernandez@dla.mil or Jason C. Wray at Jason.Wray@dla.mil.